tetano
Editor, Senior Moderator
Front Immunol
. 2024 Apr 19:15:1354349.
doi: 10.3389/fimmu.2024.1354349. eCollection 2024. Antiphospholipid antibody-related hepatic vasculitis in a juvenile after non-severe COVID-19: a case report and literature review
Qingyu Li[SUP] #[/SUP][SUP] 1 2 [/SUP], Jingya Li[SUP] #[/SUP][SUP] 1 2 [/SUP], Menglan Zhou[SUP] 3 [/SUP], Ying Ge[SUP] 4 [/SUP], Zhengyin Liu[SUP] 4 [/SUP], Taisheng Li[SUP] 3 4 [/SUP], Li Zhang[SUP] 4 [/SUP]
Affiliations
Antiphospholipid antibodies (aPL) are both laboratory evidence and causative factors for a broad spectrum of clinical manifestations of antiphospholipid syndrome (APS), with thrombotic and obstetric events being the most prevalent. Despite the aPL-triggered vasculopathy nature of APS, vasculitic-like manifestations rarely exist in APS and mainly appear associated with other concurrent connective tissue diseases like systemic lupus erythematous. Several studies have characterized pulmonary capillaritis related to pathogenic aPL, suggesting vasculitis as a potential associated non-thrombotic manifestation. Here, we describe a 15-year-old girl who develops hepatic infarction in the presence of highly positive aPL, temporally related to prior non-severe COVID-19 infection. aPL-related hepatic vasculitis, which has not been reported before, contributes to liver ischemic necrosis. Immunosuppression therapy brings about favorable outcomes. Our case together with retrieved literature provides supportive evidence for aPL-related vasculitis, extending the spectrum of vascular changes raised by pathogenic aPL. Differentiation between thrombotic and vasculitic forms of vascular lesions is essential for appropriate therapeutic decision to include additional immunosuppression therapy. We also perform a systematic review to characterize the prevalence and clinical features of new-onset APS and APS relapses after COVID-19 for the first time, indicating the pathogenicity of aPL in a subset of COVID-19 patients.
Keywords: COVID-19; antiphospholipid antibodies; non-thrombotic manifestation; pediatrics; vasculitis; vasculopathy.
. 2024 Apr 19:15:1354349.
doi: 10.3389/fimmu.2024.1354349. eCollection 2024. Antiphospholipid antibody-related hepatic vasculitis in a juvenile after non-severe COVID-19: a case report and literature review
Qingyu Li[SUP] #[/SUP][SUP] 1 2 [/SUP], Jingya Li[SUP] #[/SUP][SUP] 1 2 [/SUP], Menglan Zhou[SUP] 3 [/SUP], Ying Ge[SUP] 4 [/SUP], Zhengyin Liu[SUP] 4 [/SUP], Taisheng Li[SUP] 3 4 [/SUP], Li Zhang[SUP] 4 [/SUP]
Affiliations
- PMID: 38707895
- PMCID: PMC11066154
- DOI: 10.3389/fimmu.2024.1354349
Antiphospholipid antibodies (aPL) are both laboratory evidence and causative factors for a broad spectrum of clinical manifestations of antiphospholipid syndrome (APS), with thrombotic and obstetric events being the most prevalent. Despite the aPL-triggered vasculopathy nature of APS, vasculitic-like manifestations rarely exist in APS and mainly appear associated with other concurrent connective tissue diseases like systemic lupus erythematous. Several studies have characterized pulmonary capillaritis related to pathogenic aPL, suggesting vasculitis as a potential associated non-thrombotic manifestation. Here, we describe a 15-year-old girl who develops hepatic infarction in the presence of highly positive aPL, temporally related to prior non-severe COVID-19 infection. aPL-related hepatic vasculitis, which has not been reported before, contributes to liver ischemic necrosis. Immunosuppression therapy brings about favorable outcomes. Our case together with retrieved literature provides supportive evidence for aPL-related vasculitis, extending the spectrum of vascular changes raised by pathogenic aPL. Differentiation between thrombotic and vasculitic forms of vascular lesions is essential for appropriate therapeutic decision to include additional immunosuppression therapy. We also perform a systematic review to characterize the prevalence and clinical features of new-onset APS and APS relapses after COVID-19 for the first time, indicating the pathogenicity of aPL in a subset of COVID-19 patients.
Keywords: COVID-19; antiphospholipid antibodies; non-thrombotic manifestation; pediatrics; vasculitis; vasculopathy.